Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Siremadlin in Hepatic Impairment
NCT05599932Phase 1Completed
- Sponsor
- Novartis
- Start
- Dec 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of siremadlin in acute myeloid leukemia (AML) and solid tumor (4 arms), sponsored by Novartis. Primary endpoints: Maximum Plasma Concentration at 144 hours, Area Under the Curve to Last Measurable Concentration up to 144 hours and 8 more. Started Dec 2022; status: completed.
02
Drugs
siremadlin
03
Conditions
acute myeloid leukemia (AML)solid tumor
Beyond the preview
Go deeper on NCT05599932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05599932.